90Y-DOTATOC + amino acids

90Y-DOTATOC (Yttrium-90 DOTA-Tyr3-octreotide) is an investigational peptide receptor radionuclide therapy (PRRT) developed and studied under the leadership of Dr. M. Sue O'Dorisio at the University of Iowa. The therapy consists of the high-energy beta-emitting radioisotope yttrium-90 conjugated via the DOTA chelator to the somatostatin analog edotreotide (DOTATOC). It specifically targets somatostatin receptors (SSTRs), particularly SSTR2, which are overexpressed in various malignancies including neuroendocrine tumors, meningiomas, and pediatric solid tumors such as neuroblastoma and medulloblastoma. To protect the kidneys from radiation damage caused by the renal reabsorption of the radiolabeled peptide, the therapy is administered alongside an intravenous infusion of amino acids (typically L-lysine and L-arginine). The treatment protocol often utilizes personalized dosimetry to optimize the radiation dose delivered to the tumor while minimizing toxicity to the bone marrow and kidneys.

Other names

Yttrium-90 DOTATOCYttrium90 DOTATOCYttrium 90 DOTATOCYttrium-90 edotreotideYttrium90 edotreotideYttrium 90 edotreotide90Y-edotreotide